NIDA shifts focus of grants to translational, genetic medicine

12/7/2012 | Genetic Engineering & Biotechnology News

The National Institute on Drug Abuse has restructured its small business technology transfer and small business innovation research grant programs, which make up for roughly 2.8% of its annual budget, to focus on projects that aim to discover substance abuse treatments using translational and genetic medicine. "We're interested in areas of genetics, in terms of smoking cessation, pharmacogenomics, treatment of substance abuse, and particularly right now, issues related to prescription substance abuse," said NIDA official Jonathan D. Pollock. The NIH unit is also interested in supporting development and commercialization of biomarkers, stem cell reagents, genomic and proteomic data and related technologies.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
Boise, ID